These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26276740)

  • 1. [Eculizumab for atypical hemolytic uremic syndrome in newborn: a case report].
    Alonso-Triana YM; Perrino MJ
    Farm Hosp; 2015 Jul; 39(4):217-8. PubMed ID: 26276740
    [No Abstract]   [Full Text] [Related]  

  • 2. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab.
    Zschiedrich S; Prager EP; Kuehn EW
    Ann Intern Med; 2013 Jul; 159(1):76. PubMed ID: 23817717
    [No Abstract]   [Full Text] [Related]  

  • 5. Eculizumab in atypical hemolytic-uremic syndrome.
    Tanimoto T; Oshima Y; Kami M
    N Engl J Med; 2013 Oct; 369(14):1378-9. PubMed ID: 24088109
    [No Abstract]   [Full Text] [Related]  

  • 6. Eculizumab in atypical hemolytic-uremic syndrome.
    Kistler AD
    N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088108
    [No Abstract]   [Full Text] [Related]  

  • 7. Eculizumab in atypical hemolytic-uremic syndrome.
    Amadio A; Tejani AM
    N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088107
    [No Abstract]   [Full Text] [Related]  

  • 8. Eculizumab in atypical hemolytic-uremic syndrome.
    Ring T
    N Engl J Med; 2013 Oct; 369(14):1377-8. PubMed ID: 24088106
    [No Abstract]   [Full Text] [Related]  

  • 9. Eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Loirat C
    N Engl J Med; 2013 Oct; 369(14):1379-80. PubMed ID: 24088105
    [No Abstract]   [Full Text] [Related]  

  • 10. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.
    Alachkar N; Bagnasco SM; Montgomery RA
    Transpl Int; 2012 Aug; 25(8):e93-5. PubMed ID: 22591029
    [No Abstract]   [Full Text] [Related]  

  • 11. Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan.
    Tanimoto T; Kusumi E; Hosoda K; Kouno K; Hamaki T; Kami M
    Orphanet J Rare Dis; 2014 Apr; 9():48. PubMed ID: 24716834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3.
    Ferreira E; Oliveira N; Marques M; Francisco L; Santos A; Carreira A; Campos M
    Nefrologia; 2016; 36(1):72-5. PubMed ID: 26541438
    [No Abstract]   [Full Text] [Related]  

  • 13. Eculizumab. A less burdensome treatment for atypical haemolytic uraemic syndrome?
    Prescrire Int; 2013 Mar; 22(136):68. PubMed ID: 23593689
    [No Abstract]   [Full Text] [Related]  

  • 14. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
    Vaisbich MH; Henriques Ldos S; Watanabe A; Pereira LM; Metran CC; Malheiros DA; Modanez F; Silva JD; Vieira S; Macedo AC; Massarope B; Furusawa EA; Schvartsman BG
    J Bras Nefrol; 2013; 35(3):237-41. PubMed ID: 24100744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin].
    Beye F; Malbranche C; Tramecon D; Pernot C; Zanetta G; Mousson C; Guignard MH; Lazzarotti A
    Therapie; 2013; 68(2):119-22. PubMed ID: 23773354
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.
    Cañigral C; Moscardó F; Castro C; Pajares A; Lancharro A; Solves P; de la Rubia J; Carpio N; Sanz MA
    Ann Hematol; 2014 Aug; 93(8):1421-2. PubMed ID: 24306089
    [No Abstract]   [Full Text] [Related]  

  • 18. More on eculizumab for congenital atypical hemolytic-uremic syndrome.
    Shin JI; Lee JS
    N Engl J Med; 2009 May; 360(20):2142-3; author reply 2143. PubMed ID: 19439754
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to Eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations.
    Saini A; Emke AR; Silva MC; Perlman SJ
    Clin Pediatr (Phila); 2015 Apr; 54(4):387-9. PubMed ID: 24817079
    [No Abstract]   [Full Text] [Related]  

  • 20. Eculizumab for congenital atypical hemolytic-uremic syndrome.
    Gruppo RA; Rother RP
    N Engl J Med; 2009 Jan; 360(5):544-6. PubMed ID: 19179329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.